Key points are not available for this paper at this time.
In Australia the government must balance access to new drugs against the cost to the Pharmaceutical Benefits Scheme. Economic evaluations can be used to ensure health resources are allocated efficiently, maximising patient outcomes for every dollar spent.
Taylor et al. (Thu,) studied this question.